Quality of life of patients suffering from schizophrenia and treated with long-acting risperidone and paliperidone-palmitate
| Autor: | Mihajlović Filip, Milosavljević Aleksandar, Lekić Tanja, Gavrilović Jagoda, Janjić Vladimir |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Racionalna Terapija, Vol 10, Iss 2, Pp 17-23 (2018) |
| ISSN: | 2217-8627 1821-0538 |
| Popis: | Introduction: In recent decades, researchers devoted a lot of attention to studying the quality of life of people with mental disorders. Improving quality of life of people with schizophrenia is becoming an obligation of pharmacological therapy. The aim: The aim of the paper was to assess certain aspects of quality of life of the patients suffering from schizophrenia treated with longacting risperidone and paliperidone-palmitate and to determine the impact of socio-demographic characteristics on the quality of life of these patients. Method: The study was done as a cross-sectionalinvestigation after receiving the decision of the Ethics Committee, and it was conducted according to the principles of Good Clinical Practice. The study covered 45 patients of both sex with diagnosis of schizophrenia (MKB-10, F20.0-F20.9). The respondents were classified in two groups of 25 and 20 patients: those who received long-acting risperidone and those who received long-acting paliperidone palmitate, respectively. The assessment of the quality of life of respondents was done by a scale of personal and social impact (PSP). Socio-demographic questionnaire was used to assess the influence of socio-demographic characteristics on healthrelated quality of life. Results: Statistically significant differences were observed in personal and social functioning, in favor of patients treated with long-acting paliperidone palmitate (PSP score: 78.30 ± 5.03). The subjects of this group were more satisfied with their own health and themselves than those who were treated by long-acting risperidone. Data obtained by analyzing sociodemographic questionnaires indicate that patients who received long-acting risperidone had more hospitalizationsannually (r = 0.03) compared to patients treated by the paliperidone-palmitate. There was also a statistically significant increasein absenteeism (r = 0.009) from work in patients receiving long-acting risperidone. Conclusion: Our study showed higher scores ofpersonal and social functioning in the group of patients treated with long-acting paliperidonepalmitate. Longer dosing interval of paliperidone-palmitate enables greater mobility of the patients within the society and diminished sense of stigmatization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|